Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume – Still a Buy?

Genmab A/S (NASDAQ:GMAB) shares saw strong trading volume on Wednesday . 4,599,016 shares traded hands during mid-day trading, an increase of 203% from the previous session’s volume of 1,518,271 shares.The stock last traded at $19.79 and had previously closed at $19.58.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Down 0.7 %

The firm’s 50-day moving average price is $21.04 and its 200 day moving average price is $23.76. The company has a market cap of $13.02 billion, a price-to-earnings ratio of 19.10, a P/E/G ratio of 0.55 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the firm posted $0.47 earnings per share. Analysts forecast that Genmab A/S will post 1.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently added to or reduced their stakes in the company. Legacy Wealth Asset Management LLC increased its stake in Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after purchasing an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. lifted its position in Genmab A/S by 10.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after acquiring an additional 1,121 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after acquiring an additional 1,413 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.